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Background: Immune homeostasis requires fully functional Tregs with a stable
phenotype to control autoimmunity. Although IL-34 is a cytokine first described
as mainly involved in monocyte cell survival and differentiation, we recently
described its expression by CD8+ Tregs in a rat model of transplantation tolerance and by activated FOXP3+ CD4+ and CD8+ Tregs in human healthy
individuals. However, its role in autoimmunity and potential in human diseases
remains to be determined.
Methods: We generated Il34−/− rats and using both Il34−/− rats and mice, we
investigated their phenotype under inflammatory conditions. Using Il34−/− rats,
we further analyzed the impact of the absence of expression of IL-34 for CD4+
Tregs suppressive function. We investigated the potential of IL-34 in human disease to prevent xenogeneic GVHD and human skin allograft rejection in immune
humanized immunodeficient NSG mice. Finally, taking advantage of a biocollection, we investigated the correlation between presence of IL-34 in the serum and
kidney transplant rejection.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the
original work is properly cited.
© 2022 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.
Clin. Transl. Med. 2022;12:e988.
https://doi.org/10.1002/ctm2.988

wileyonlinelibrary.com/journal/ctm2

1 of 17

20011326, 2022, 8, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/ctm2.988, Wiley Online Library on [01/11/2022]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

Received: 4 February 2022

FREUCHET et al.

Results: Here we report that the absence of expression of IL-34 in Il34−/− rats
and mice leads to an unstable immune phenotype, with production of multiple auto-antibodies, exacerbated under inflammatory conditions with increased
susceptibility to DSS- and TNBS-colitis in Il34−/− animals. Moreover, we revealed
the striking inability of Il34−/− CD4+ Tregs to protect Il2rg−/− rats from a wasting
disease induced by transfer of pathogenic cells, in contrast to Il34+/+ CD4+ Tregs.
We also showed that IL-34 treatment delayed EAE in mice as well as GVHD and
human skin allograft rejection in immune humanized immunodeficient NSG
mice. Finally, we show that presence of IL-34 in the serum is associated with
a longer rejection-free period in kidney transplanted patients.
Conclusion: Altogether, our data emphasize on the crucial necessity of IL-34
for immune homeostasis and for CD4+ Tregs suppressive function. Our data
also shows the therapeutic potential of IL-34 in human transplantation and
auto-immunity.
KEYWORDS

autoimmunity, CRISPR/Cas9, Foxp3, IL-34, immunotherapy, knockout, rat, tolerance, Treg

Highlights
– Absence of expression of IL-34 in Il34−/− rats and mice leads to an unstable immune phenotype, with a production of multiple auto-antibodies and
exacerbated immune pathology under inflammatory conditions.
– Il34−/− CD4+ Tregs are unable to protect Il2rg−/− rats from colitis induced by
transfer of pathogenic cells.
– IL-34 treatment delayed EAE in mice, as well as acute GVHD and human skin
allograft rejection in immune-humanized immunodeficient NSG mice.

1

INTRODUCTION

IL-34 is a homodimeric cytokine binding three distinct
receptors or co-receptors, namely CSF-1R (CD115), CD138
(syndecan-1) and PTPζ.1,2 CSF-1 is another ligand of
CD115 but binds with a lower affinity than IL-34, and
they both induce survival and differentiation of monocytes towards type 2 ‘regulatory’ macrophages.3,4 However,
IL-34 and CSF-1 spatio-temporal expressions are mainly
distinct, and CSF-1 does not bind to CD138 and PTPζ.5
Thus, they have been shown to exert also non-overlapping
roles.5
We have recently demonstrated that IL-34, but not CSF1, is significantly overexpressed in antigen-specific CD8+
Tregs from long-term tolerant transplanted rats (treated
with CD40Ig, a chimeric molecule blocking the CD40CD40L pathway) versus CD8+ Tregs from naive rats.6–8
Further analysis showed that IL-34 expression in human
T cells is restricted to, not only activated FOXP3+ CD8+
Tregs, but also to FOXP3+ CD4+ Tregs with about 50%

of the FOXP3+ Tregs expressing IL-34.6,9 We also showed
that treatment using an AAV encoding IL-34 alone or
together with a short suboptimal dose of rapamycin efficiently delayed or inhibited allograft rejection in vivo in
rats through differentiation of tolerogenic macrophages
responsible, in turn, for induction of CD4+ and CD8+
Tregs. In this model, the CD4+ and CD8+ Tregs were
responsible for the long-term tolerance induction effect
of the treatment. In vitro, we showed the IL-34 inhibited
both rats and humans effector CD4+ CD25− T cells proliferation and induced human Foxp3+ CD4+ and CD8+
Tregs expansion.6,10 In addition, a suppressive role for
IL-34 was also demonstrated by others11 in rodent liver
transplantation models.
Although Il34LacZ/LacZ mice have been studied and no
spontaneous autoimmunity or inflammatory diseases were
reported,12 we speculated that it could be due to lack of an
inflammatory/autoimmune stimulus. Indeed, in human,
increased IL-34 serum levels have been associated with
inflammatory diseases1,2 ; however, IL-34 role was not
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properly described and mostly circumstantial. Thus, the
contribution of IL-34 in immune homeostasis, Treg function, as well as its role in autoimmunity and human
transplant rejection remains unclear and needs to be further addressed. Herein, we generated Il34−/− rats and
using both Il34−/− rats and mice, we investigated their phenotype under inflammatory conditions. Using Il34−/− rats,
we further analysed the impact of the absence of expression of IL-34 for CD4+ Tregs suppressive function. We
investigated the potential of IL-34 in human disease to
prevent xenogeneic GVHD and human skin allograft rejection in immune humanized immunodeficient NSG mice.
Finally, taking advantage of a biocollection, we investigated the correlation between presence of IL-34 in the
serum and kidney transplant rejection.
Altogether, our study emphasizes the crucial role of
IL-34 for immune homeostasis and for CD4+ Tregs suppressive function and the therapeutic potential of IL-34 in
human transplantation and autoimmunity.

2

RESULTS

2.1
At homeostasis, IL-34 participates in
microglia development and regulates
cytokines, enzymes and auto-antibodies
production
To gain further knowledge on the immunoregulatory role
of IL-34, we generated an Il34-deficient rat model using
CRISPR/Cas9 targeting exon 3 of the rat Il34 gene. The
non-homologous end joining repair mechanism inserted
a C base, leading to a STOP codon apparition (Figures 1A
and S1A). The founder animal was mated with an Il34+/+
animal, the mutation was transmitted to the progeny,
and homozygous Il34−/− animals were generated as confirmed by heteroduplex mobility assay on an automated
microfluidic chip capillary electrophoresis system and
sequencing.13,14 In the absence of available anti-rat IL-34
antibody, we confirmed the knockout using quantitative
RT-PCR and observed a major decrease of Il34 mRNA
expression in Il34−/− animals compared to littermates
Il34+/+ animals (Figure 1B). Residual mRNA detected
was due to mRNA being produced with an immature
STOP codon before rapid degradation. The Il34−/− animals looked visually healthy at steady state with normal
appearance (Figure S1B), growth (Figure S1C) and bone
mass (Figure S1D,E). However, in accordance with the role
of IL-34 reported for microglia development and maintenance in the mouse,5 brain analysis showed decreased
microglia (CD11b/c+ cells) in the hippocampus, but not
the cerebellum of the Il34−/− animals (Figures 1C,D
and S1F). Sera analysis showed an increase of ALT and
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ALT/LDH enzyme levels ratio and a trend for AST and
alkaline phosphatase (Figure 1E), suggesting mild liver
injury. Interestingly, we also observed a strong increase
of auto-antibodies production against IFN-α1, −α2, −α4,
-α7, -α11 and anti-IL-22 in Il34−/− rats (Figure 1F) (no
evidence for anti-IL-17A/F Ab), increased inflammatory
chemokine MIP-2 and decreased eosinophil chemotactic
proteins (eotaxin), as well as regulatory TGF-β3 (Figure 1G)
(no changes for TGFβ1/2, IL-1α/β, -2, -4, -5, -6, -10, -12p70,
-13, -17A, G-CSF, GM-CSF, TNFα, IFNγ, GROα, MCP1, -3, MIP-1α, Rantes and IP-10; Figure S2A), altogether
suggesting auto-inflammation and an important role for
IL-34 in auto-antibodies development and cytokines production. Serum levels of immunoglobulin isotypes were
normal and antibodies directed against dsDNA were similar to Il34+/+ rats (Figure S2B,C). Histological analysis
of organs did not show any evidence of tissue lesions
or inflammatory infiltrates (Figure S2D). We investigated
whether, as compensatory mechanisms that could mitigate the autoimmune symptoms, CSF-1 was upregulated
and indeed found significantly higher levels of CSF-1 in
the sera of the Il34−/− animals (>6-month old) (Figure 1H),
suggesting a negative regulation of CSF-1 by IL-34.
Altogether, these results demonstrate a role for IL-34 in
rat microglia development and a critical role for regulating
auto-antibody development and cytokine production.

2.2
In rat, IL-34 deficiency leads to a
decreased number of CD8+ T cells and
increased susceptibility to colitis
We then further analysed the impact of the deficiency on
immune cells in mice and rats. Although absolute numbers of cells were slightly decreased in thymus, spleen and
blood of Il34−/− rats (Figure 2A), thymic subpopulations,
B cell subsets and myeloid cell subsets in spleen were not
modified (Figure S3A–C). In contrast, we observed a significant decrease of CD8+ T cells from spleen and blood
in Il34−/− rats versus Il34+/+ rats, but not for CD4+ T
cells (Figure 2B). In addition, a further analysis of lymphocyte function revealed a higher proliferation capacity
of CD8+ CD45RChigh (effector) T cells,10,15,16 but not of
CD4+ CD25− effector T cells, in response to a polyclonal
stimulation (Figure 2C), altogether suggesting a role for
IL-34 in CD8+ T cell number and proliferative capacity.
The phenotype of FOXP3+ or FOXP3− CD4+ or CD8+ T
cells did not reveal differences in Il34−/− rats versus Il34+/+
rats (Figure S3D,E) and we observed similar in vitro proliferation capacity for both CD4+ and CD8+ Tregs (Figure
S3F).
Gaining insights towards the role of IL-34 in T cell
development/function, we next assessed the impact of the
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F I G U R E 1 Generation of Il34−/− rats by CRISPR/Cas9 and characterization. (A) Schematic representing the Cas9/sgRNA targeting the
exon three of the Il34 gene inducing a genomic DNA cut (arrow). PAM sequence is in red. (B) Il34 mRNA expression was assessed by
quantitative real-time PCR in spleen, liver and brain of Il34+/+ (n = 7–10) and Il34−/− rats (n = 7–9). Results are normalized to Hprt and
expressed as 2−ΔΔCT ± SEM. (C) Confocal microscopy was performed on Il34+/+ and Il34−/− rats frozen brains stained with an antibody
directed against CD11b/c (green) to identify microglia and DAPI (blue). Arrows indicate a representative stained cell. Original magnification,
×800. Scale bar 50 μm. (D) Quantification of positive CD11b/c staining areas in Il34+/+ and Il34−/− rats’ hippocampus (Il34+/+ , n = 8; Il34−/− ,
n = 8) and cerebellum (Il34+/+ , n = 3; Il34−/− , n = 3) slices. Each dot represents an individual animal and results are expressed as
mean ± SEM. (E) Plasma from 4-month-old Il34+/+ (n = 9) and Il34−/− (n = 14) rats was used to quantify AST, ALT, ALT/LDH ratio and
alkaline phosphatase. (F) Auto-antibodies against interferon (IFN)-α1, α2, α4, α7, α11 and IL-22 were assessed in sera by luciferase
immunoprecipitation systems (LIPS) assay (>6-month-old Il34+/+ rat, n = 10 and Il34−/− rat, n = 16). (G) Eotaxin, TGF-β3 and MIP-2 protein
levels were quantified by Luminex assay in the sera of >6-month-old Il34+/+ (n = 10) and Il34−/− (n = 16) rats. (H) CSF-1 protein was
quantified by ELISA in the sera of >6-month-old Il34+/+ (n = 8) versus Il34−/− rats (n = 12). Results are expressed as mean ± SEM.
Mann–Whitney U test, *p < .05, **p < .01, ***p < .001, ****p < .0001
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F I G U R E 2 IL-34 global deficiency increases CD8+ T cells proliferation capacity and colitis severity. (A) Absolute numbers of cells were
analysed in thymus (2-month old), spleen and blood (>10-month old) of Il34+/+ (n = 5–10) and Il34−/− (n = 6–11) rats. (B) Absolute numbers
of T cell subsets were analysed in spleen (left) and blood (right) of >10-month-old Il34+/+ (n = 5–10) and Il34−/− (n = 6–11) rats using markers
described in the Supporting Information section. (C) Effector TCRαβ+ CD4+ CD25− (CD4+ Teffs) and TCRαβ+ CD4− CD45RChigh (CD8+ Teffs)
from Il34+/+ (n = 7–8) or Il34−/− (n = 5–7) rats were sorted and tested for proliferation capacity over 2-day culture with an increasing
concentration of anti-CD3 (.25–.5–1 μg/ml) and anti-CD28 (10 μg/ml) mAbs. Results are represented as mean ± SEM. (D) Left panel:
Schematic of the acute DSS model: 5.5% of DSS in drinking water was given for 7 days to 9-week-old male Il34+/+ (n = 8) or Il34−/− rats
(n = 11). Il34+/+ control rats were given regular water (n = 8). Right panel: A clinical score of colitis severity was established and followed
every day. (E) At day 7, rats were sacrificed and the colon length measured and H&E stained. Results are represented as mean ± SEM and
representative of two independent experiments. Colon sections of Il34+/+ and Il34−/− rats treated or not with 5.5% of DSS were stained with
H&E. Histopathological enlarged images (upper panel, scale bar = 1000 μm) and focused on epithelial injury (lower panel, scale
bar = 250 μm) are presented. In colon, crypts rarefaction and/or cell infiltration of the lamina propria and the submucosa were present
(indicated by arrows). Data are representative of eight animals in each group. Mann–Whitney U test, a two-way ANOVA with a Bonferroni
post-test for clinical score and log-rank test for survival analysis, *p < .05, ****p < .0001

global deficiency in an inflammatory environment using
the acute DSS colitis model. For 7 days, 5.5% DSS given
in drinking water to Il34+/+ and Il34−/− rats resulted in
an increased severity at all time points in Il34−/− animals
compared to Il34+/+ animals (Figure 2D). Moreover, analysis of colon length and H&E analysis at day 7 showed
that the colon of Il34−/− rats was shorter than Il34+/+ and
control animals and showed histological signs of tissue
destruction and leukocyte infiltration (Figure 2E), indicating more inflammation in the colon of Il34−/− rats. The

mean colon length of untreated Il34−/− rats was 26.63 cm
(n = 3) similar to control Il34+/+ rats (data not shown). We
also observed that DSS-induced colitis in Il34−/− rats led
to increased levels of pro-inflammatory cytokines Il6, Il1b,
Il22 and a trend for an increase for Il17a, all involved in gut
inflammation, whereas Ifng was decreased (Figure S4A).
However, we observed no significant differences between
Il34+/+ and Il34−/− rats. Altogether, our data demonstrate
that the lack of IL-34 upon DSS-induced colitis increases
its severity.
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2.3
IL-34 deficiency leads to defective
suppressive function of CD4+ Tregs in vivo

2.4
Il34−/− mice are more prone to
autoimmunity

As we previously showed that around 50% of FOXP3+
CD4+ and CD8+ Tregs express IL-34,6 we then tested
CD4+ CD25+ (CD4+ Tregs) and CD8+ CD45RClow/−
(CD8+ Tregs) Tregs from Il34−/− rats for their capacity to control in vivo wasting disease by i.v. transfer
of T CD4+ CD45RChigh effector cells in Il2rg−/− rats
(Figure 3A). Il2rg−/− rats are immunodeficient, and they
lack or have greatly reduced numbers of T, NK and B
cells.17 The use of Il2rg−/− rats reproduces a classical
model of colitis in both immunodeficient mice (nude or
different mutations in Rag or Il2rg genes) and rats (nude).
In both species, an immunodeficient recipient receiving
CD4+ CD45RBhigh (mouse) or CD4+ CD45RChigh (rat) cells
causes a wasting disease with intestinal and liver lesions,
among other organs.17 Strikingly, Il34−/− CD4+ Tregs were
unable to control the development of wasting disease in
Il2rg−/− animals and death occurred in a similar kinetic
rather than without CD4+ Tregs, in contrast to CD4+
Tregs from Il34+/+ rats that efficiently controlled wasting
disease development (Figure 3B), demonstrating the
critical role of IL-34 in CD4+ Tregs–mediated suppressive
activity. Histological analysis of the liver and colon from
all groups confirmed the cell infiltration and tissue lesions
in Il2rg−/− animals injected with CD4+ Teff cells without
or with CD4+ Tregs from Il34−/− animals, in contrast to
animals injected with CD4+ Treg from Il34+/+ animals
(Figure 3C). Although we did not observe a protective
role of CD8+ Tregs in this model for both Il34+/+ and
Il34−/− CD8+ Tregs (Figure 3D,E), we observed decreased
infiltration in liver and colon in animals injected with
CD8+ Tregs from Il34+/+ animals compared to animals
injected with CD4+ Teff cells with or without CD8+ Tregs
from Il34−/− animals (Figure 3E), suggesting that Il34−/−
CD8+ Tregs were less efficient.
To understand how IL-34 deficiency had modified the
function of both CD4+ and CD8+ Tregs in Il34−/− versus Il34+/+ rats, we analysed their transcriptome using
differential gene expression (DGE)-RNAseq. Intriguingly,
the transcriptomic landscape of CD4+ and CD8+ Tregs
in Il34−/− rats only significantly differed for one gene,
Dnaja1, a co-chaperone of heat shock proteins (HSPs),18
identically increased in CD4+ and CD8+ Tregs from
Il34−/− rats versus CD4+ and CD8+ Tregs from Il34+/+
rats (Figure 3F). Thus, although the role of the increased
mRNA expression of Dnaja1 needs to be explored in future
work, the major defect in suppressive capacity observed for
Tregs from Il34−/− rats is likely not due to a major effect
on Tregs direct functions but rather on downstream effects
of IL-34 produced by Tregs, mainly through induction of
tolerogenic macrophages.4,6,9

To take advantage of the Il34−/− mouse model,12 we then
assessed susceptibility to autoimmune diseases in Il34−/−
mice in models of TNBS-induced colitis (Figure 4A) and
experimental autoimmune encephalomyelitis (EAE) triggered by MOGp35–55 (Figure 4B).12 In the TNBS-induced
colitis model, we observed a shorter colon length at day 3 in
Il34−/− mice compared to Il34+/+ and Il34+/+ control mice
(Figure 4A), indicating more severe inflammation; however, we did not observe significant differences in weight
loss (Figure S4B). The mean colon length of untreated
Il34−/− mice was 9.43 ± .28 cm (n = 3) similar to control Il34+/+ mice (9.29 ± .17 cm) (data not shown). We
next investigated the impact of IL-34 deficiency in the
EAE model as IL-34 could have a protective role through
Treg maintenance and microglia development.19,12,6 In the
EAE model, the Il34−/− mice developed EAE faster and
more severely and most Il34−/− mice died by day 20 as
shown by the survival curve (Figure 4B), in contrast to
the Il34+/+ animals. In addition, Il34−/− mice lost more
weight than the controls; however, the overall clinical
score was not significantly different (Figure S4C). When
we assessed the therapeutic potential of IL-34 therapy
in autoimmunity in the EAE model, we observed that
the injection of an adenovirus coding for murine IL-34
in association with a suboptimal dose of rapamycin led
to a delayed EAE development compared to the control
groups, that is, null adenovirus associated or not with
rapamycin (Figure 4C, left). We observed that the mice
treated with Ad-null + rapamycin developed signs of EAE
faster than the group Ad-IL34 + rapamycin; however,
the score remains low until day 20–25 before increasing,
whereas the group treated with Ad-IL34 remained stable
(Figure 4C, right).
Thus, altogether, IL-34 deficiency in mice leads to an
unstable immune phenotype, with increase susceptible
to autoimmunity and inflammation in a specific environment. Moreover, supplementing IL-34 is beneficial in
neurodegenerative autoimmune diseases in mice.

2.5
hIL-34 protein infusion with a
suboptimal dose of rapamycin
demonstrates regulatory therapeutic
properties
Our data so far present a critical role for IL-34 in
Treg-mediated suppression and although we previously
showed that IL-34 played a role in a transplantation
model in rats and mice and that IL-34 inhibited human
Teff cells in vitro,6,9 the question of whether IL-34 has
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F I G U R E 3 Il34−/− CD4 Tregs fail to protect from the wasting disease. (A) Schematic showing the wasting disease model induction. (B)
Six-week-old Il2rg−/− rats were injected i.v. with 2.5 × 106 TCRαβ+ CD4+ CD45RChigh Teffs from Il34+/+ rats (Teffs; n = 12) in association or not
with TCRαβ+ CD4+ CD25+ CD127low Tregs (CD4+ Tregs; 3.5:1 Teffs:Tregs ratio) from Il34+/+ (n = 8) or Il34−/− (n = 8) rats in seven independent
experiments. (C) Liver and colon sections of injected Il2rg−/− rats were stained with haematoxylin eosin saffron (HES) (original
magnification ×10, scale bar 20 μm). Data are representative of six animals in each group. (D) Six-week-old Il2rg−/− rats were injected i.v. with
TCRαβ+ CD4+ CD45RChigh Teffs from Il34+/+ rats (Teffs) in association with or not with TCRαβ+ CD4− CD45RClow/− Tregs (CD8+ Tregs; 2.1:1
Teffs:Tregs ratio) from Il34+/+ (n = 7) or Il34−/− (n = 7) rats in five independent experiments. (E) Liver and colon sections of injected Il2rg−/−
rats were stained with HES (original magnification ×10). Data are representative of six animals in each group. (F) (left) 3′ DGE-RNA
sequencing analysis was performed on sorted and non-stimulated TCRαβ+ CD4+ CD25+ CD127low Tregs (CD4+ Tregs) and
TCRαβ+ CD4− CD45RClow/− Tregs (CD8+ Tregs) from 8–10-week-old Il34+/+ (n = 7) and Il34−/− rats (n = 8–9). The table recapitulates the
results of Dnaja1, the only gene differentially expressed between Il34−/− versus Il34+/+ CD4+ Tregs and Il34−/− versus Il34+/+ CD8+ Tregs.
(Right) Transcript levels of Dnaja1 (UPM) log scale in CD4+ and CD8+ Treg in Il34+/+ or Il34−/− rats. Mann–Whitney U test, a two-way
ANOVA with a Bonferroni post-test for clinical score and log-rank test for survival analysis, *p < .05, **p < .01, ***p < .001, ****p < .0001
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F I G U R E 4 Il34−/− mice are more susceptible to autoimmune diseases. (A) Schematic showing the TNBS-induced colitis. The model
was performed on Il34+/+ versus Il34−/− mice (n = 11–13) via the intrarectal administration of TNBS (100 mg/kg) in 50% ethanol. Control
Il34+/+ mice were injected with 50% ethanol alone or not treated. Mice colon length was measured at day 3 post-injection. Each dot represents
an animal. Results are represented as mean ± SEM. (B) Schematic showing the MOG-induced experimental autoimmune encephalomyelitis
(EAE) model in mice. Adult Il34+/+ (n = 14) and Il34−/− (n = 10) C57BL/6J mice of 8-week old were immunized with the peptide MOG35–55
and mycobacterium for EAE induction. The development of the disease was followed by a daily weight and scoring assessment. (C) Schematic
showing the IL-34 overexpression in the MOG-induced EAE model. Adult Il34+/+ mice of 8-week old were i.v. injected with an adenovirus
coding for mouse IL-34 (Ad-IL-34) or a control (Ad-null) 2 days before inducing the EAE. Rapamycin was administered or not every day for 15
days at a dose of .25 mg/kg/d (i.p. injection; grey area). The development of the disease was followed by a daily weight and scoring assessment.
Results are represented as mean ± SEM. Mann–Whitney U test or two-way ANOVA and a Bonferroni posttest for the score analyses. *p < .05;
**p < .01, ***p < .001, ****p < .0001

the capacity to inhibit transplant rejection and induce
transplant tolerance in an immune response by human
cells still remains. Thus, we used transplantation models in immune-humanized immunodeficient NSG mice
(Figure 5A,B) in which we administered recombinant
human IL-34 (rhIL-34) protein using mini-osmotic pumps
delivering a constant rate of protein and assessed xenogeneic GVHD or human skin transplant rejection. We

previously demonstrated that the administration of IL-34
alone (.8 mg/kg/2 d) did not delay GVHD development
compared to PBMC alone;9 thus, we used IL-34 together
with a suboptimal dose of rapamycin. Administration for
14 days of rhIL-34 protein in association with a suboptimal dose of rapamycin for 10 days resulted in significantly
delayed GVHD development with an induction of longterm survival in 25% of the recipients (Figure 5A) and a
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F I G U R E 5 Human IL-34 recombinant protein administration delays graft-versus-host-disease (GVHD) as well as skin allograft rejection
in humanized NSG mice. The therapeutic potential of IL-34 was tested in (A) GVHD and (B) human skin graft allogeneic rejection models in
humanized immunodeficient NSG mice. (A) IL-34 was administered with a mini-osmotic pump delivering a constant rate for 14 days
(.42 μg/h) with or without rapamycin (.4 mg/kg/d for 10 days). (A) For GVHD, 1.5 × 107 fresh PBMCs were i.v. injected in 1.5-Gy irradiated
8–12-week-old NOD/SCID/IL2rg−/− (NSG) mice, and the survival of mice was measured by weight loss. (B) For skin allograft rejection, 5 × 106
fresh PBMCs were i.v. injected in mice grafted with human skin 4 weeks before. Graft survival was scored on macroscopic signs of rejection
from 0 to 5 and considered rejected at a score of 3. Log-rank tests for survival analysis. *p > .05, **p < .01 and ***p < .001

significant induction of long-term skin graft tolerance in
50% of the recipients (Figure 5B), demonstrating the potential of this therapeutic strategy. Analysis of the proportion
of hCD45+ cells showed a decrease in animals treated
with rapamycin alone versus control animals and equal
inhibition in animals co-treated with rapamycin and rhIL34 in the acute GHVD model (Figure S5A), whereas in
the human skin transplantation model, the proportion of
hCD45+ cells was not modified (Figure S5B). Cell subpopulation frequencies (CD3+ , CD14+ , CD19+ , CD56+ ), CD4+
and CD8+ Teff/Tregs cells were also not impacted by IL-34
treatment in both models (Figure S5C,D). These results can
be explained by the inhibition of T effector development
and/or function rather a direct inhibition of human lymphocyte proliferation by rapamycin and IL-34. Whether
this is due to an increase in Tregs function needs further
studies.

2.6
Pre-transplantation human IL-34
serum levels, but not of CSF-1, is a
prognostic maker of a higher rejection-free
episode
We finally assessed the potential use of IL-34 as a
biomarker in organ transplantation compared to CSF-1
using serum samples from the DIVAT cohort biocollection (Table S3). We quantified IL-34 and CSF-1 by ELISA

before (Pre-Tx) and within 18 months after kidney transplantation (Post-Tx). Moreover, the outcome of the graft is
known during the 18 months, that is, stable graft function,
free of rejection episodes or with episodes of acute rejection, was used to identify stable patients versus rejection
patients (Figure 6A–D). We first determined the detectability of IL-34 based on the detection threshold: 37.5 pg/ml,
that is, the lowest concentration of the standard curve
provided by the manufacturer in the sera of patients. IL34 serum levels were detectable (≥37.5 pg/ml) in around
22% of patients in the different groups (Figure S6A) with
increased levels in patients who had experienced a rejection compared to stable patients at the post-transplantation
period (Figures 6A and S6D). In contrast, CSF-1 was
detectable in most individuals and levels were higher
in pre-transplantation compared to post-transplantation
as well as in healthy volunteers. CSF-1 levels were also
higher in post-transplantation with rejection versus stable
patients (Figure 6B). We further analysed the correlation
between IL-34/CSF-1 and the clinical outcome to determine the possibility of using IL-34 or CSF-1 as a prognosis
biomarker. We split patients with rejection episodes in two
groups based on IL-34 detectability (≤37.5 pg/ml versus
≥37.5 pg/ml) (FigureS 6C and S6A) or CSF-1 mean expression for all patients (≤2660.94 pg/ml vs. ≥2660.94 pg/ml)
(Figure 6D) in serum before transplantation and analysed the graft survival period before acute rejection
episode occurrence. Interestingly and unlike CSF-1, the
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F I G U R E 6 Pre-transplantation IL-34 levels as a marker of higher rejection-free episodes in human kidney transplant patients. (A) IL-34
and (B) CSF-1 were quantified in the serum of healthy volunteers (n = 30 and n = 20, respectively) and in patients before (Pre-Tx) and after
(Post-Tx) transplantation with a stable graft function or having had ≥1 episode of acute rejection within the 18 months following Tx (see
Table S3 for clinical characteristics; pre-Tx: rejection patients n = 71 and n = 65, stable patients n = 101 and n = 14; post-Tx: rejection patients
n = 42 and n = 22, stable patients n = 71 and n = 15 for IL-34 and CSF-1 serum levels respectively). (C and D) Graft survival of patients with an
acute rejection episode occurrence according to pre-Tx IL-34 detectability (undetectable: ≤37.5 vs. detectable: ≥37.5 pg/ml) (C) or CSF-1 mean
expression (below vs. above 2660.94 pg/ml) (D). Mann–Whitney U test and log-rank tests for survival analysis. *p > .05, **p < .01, ***p < .001
and ****p < .0001

proportion of patients without rejection episodes in
patients with IL-34 levels ≥37.5 pg/ml before transplantation was significantly higher than the one of patients with
IL-34 below this level. This statistical correlation was specific when measured before transplantation as IL-34 levels
in serum after transplantation did not predict graft outcome (Figure S6B,C). Our results thus suggest that IL-34
can act as a prognosis biomarker before transplantation.

3

DISCUSSION

Here, we demonstrated IL-34 as a critical actor of Tregmediated suppression, playing an important role in homeostasis and control of immune responses. IL-34 expression
in the T cell lineage seems to be restricted to FOXP3+ CD4+

and CD8+ Tregs6,9 acting as a significant suppressor component of their activity. IL-34 is also expressed by other cell
subsets such as neurons playing as well a protective role for
microglia.20,21
At steady state, the overall phenotype of Il34−/− rats
remained similar to the one of Il34−/− mice12,19 with
no evident developmental or pathological signs with the
exception of a decrease in microglia. There has not been
a thorough description of the distribution and function of
immune cell subsets in Il34−/− mice or on the response
to inflammatory/autoimmune stimuli, as described here
for Il34−/− animals. The increased expression of autoantibodies in Il34−/− rats is intriguing suggesting a role
for IL-34, the regulation of antibody production. CD138, a
co-receptor of IL-34, is expressed by plasma cells and binding of IL-34 to CD138 stimulates migration but does not
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transduce signalling in the absence of CSF-1R. Plasma
cells are negative for CSF-1R; however, the expression
of PTPz has not been reported on plasma cells; thus,
IL-34 could potentially impact plasma cells through
CD138. These auto-antibodies include anti-IFN-I antibodies that in addition to the role of pro-inflammatory
monocytes/macrophages in the cytokine storm leading
to severe acute respiratory distress syndrome and multiorgan pathology observed in SARS-CoV-2, infection could
suggest a role for IL-34 in COVID-19 patients22,23 and a
link between IL-34 and AIRE in T cell education in the
thymus as high titres of IFNα auto-antibodies are found
in APECED patients14,24 and Aire−/− rats25 which harbour
inborn errors in AIRE, which is responsible for thymic
expression of ectopic self-antigens and is thus responsible for negative T cell selection and Treg education in
the thymus. The presence of anti-IFNα and anti-IL-22
auto-antibodies could also be linked to the mild liver
injury observed in Il34−/− rats.26 Further investigation on
the impact of IL-34-deficiency in the gut-liver axis and
whether IL-34 deficiency may exacerbate the complications observed in caecal ligation and puncture models
would be interesting.27
IL-34 deficiency in rats led to a mild immune phenotype
in vivo at resting state, probably due to CSF-1 overexpression that may partially compensate IL-34 deficiency
in their common overlapping functions, particularly in
monocyte and macrophage differentiation. These results
suggest a negative regulation of CSF-1 by IL-34, complementary to the positive regulation of CSF-1 on IL-34
previously described.28 Despite that CSF-1 could replace
activities of IL-34, we still observed some features of a
disturbed immune system and differences on the CD8+
T cells lineage distribution pattern. However, upon challenges, we revealed an increased susceptibility to colitis.
Even though we did not find any perturbation in myeloid
distribution in the gut at steady state (data not shown),
one explanation could be that the inflammatory environment could not be counterbalanced by the action of IL-34
on macrophage polarization leading to a greater severity
in deficient animals. In the EAE model, the action of IL34 can be mediated either through the development of
microglia5 or through Treg activity both in the CNS and
periphery. We did find accelerated EAE development in
Il34−/− mice compared to Il34+/+ mice as by day 15 almost
all Il34−/− mice had lost >20% weight, but we did not
find significant differences in the score. Overexpression of
IL-34 was beneficial and significantly delayed EAE development showing a therapeutic potential of IL-34 in the
initial phases of inflammatory CNS diseases. In this model,
we used a suboptimal dose of rapamycin, which found
that, compared to higher doses given alone, it has a minor
effect on the clinical course of the disease, as we previously
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showed that there is a synergistic effect of rapamycin and
IL-34 on a model of acute graft rejection in rats6 and to
benefit from the promoting effect of rapamycin on Tregs.
Rapamycin has been used in the EAE and transplantation
models in this manuscript and although it is not the main
treatment in the corresponding disease in humans, multiple sclerosis and aGVHD, there have been studies showing
that its use can be of interest. Rapamycin has been used
to alleviate EAE in mice29,30 and has been very recently
proposed as a treatment to screen for new therapies in multiple sclerosis.31 More importantly, rapamycin has been
used in multiple sclerosis patients32 (https://clinicaltrials.
gov/ct2/show/NCT00095329). In aGVHD, rapamycin has
been used in recent translational work, which has been
done in the humanized NSG model33 as well as in clinical trials.34,35 When we specifically studied the impact
of the deficiency in Treg subsets, we revealed a clear
defect in the IL-34-deficient CD4+ Tregs-suppressive function where they fail to protect from the wasting disease.
This could be due to an insufficient differentiation of
M2-like macrophages. This is reminiscent of our observations that IL-34 induces immune tolerance in a model
of organ transplantation through M2 macrophages and
downstream induction of Treg,9 creating a positive regulatory loop. In in vitro suppressive assay, we could not find
a significant defect of suppressive capacity of CD4+ and
CD8+ Tregs, but this might be due to the setting in which
this assay is performed using irradiated allogeneic T cells
depleted-splenocytes and analysis after 6 days incubation
(data not shown). Interestingly, transcriptomic analysis of
T cells revealed the upregulation only of Dnaja1 in both
Il34−/− CD4+ and CD8+ Tregs compared to Il34+/+ rats.
Dnaja1 encodes for a protein belonging to the HSP40 acting
as an HSP70 co-chaperone. One report has demonstrated a
regulatory role of Dnaja1 where it inhibits T cell proliferation and induces IL-10 production by PBMC in rheumatoid
arthritis patients.36 Further work needs to be done in order
to comprehend the link between IL-34 and Dnaja1; however, this overall shows that IL-34 has overall no impact on
Treg transcriptomic profile itself, and this was confirmed
by analysing the transcriptomic profile of Tregs following a
short stimulation (data not shown). Thus, the loss of function we observe in the wasting disease model can be exclusively attributed to the lack of IL-34 production by Tregs.
IL-34 upregulation has been associated with certain but
not all autoimmune diseases. However, the exact contribution of IL-34 in these diseases has not been elucidated
as IL-34 upregulation could be a compensatory tolerogenic
mechanism, thus a consequence rather than a cause.1,2
Moreover, it is important to take into consideration that
although IL-34 and CSF-1 share the CSF-1R that could
explain results through M2 cells, IL-34 has two other
receptors or co-receptors, PTPzeta and CD138, expressed
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on other cell types, which could also participate in its
final effects.2,5 IL-34 was shown to delay solid organ graft
rejection in animal models and associated with a delayed
liver rejection in human.6,11 Although in our previous work
we investigated the potential of ex vivo expanded Treg
in the presence of IL-34 to inhibit GVHD in humanized
NSG mice,9 here, we demonstrate the potential of using
directly IL-34 as an immunotherapy in vivo in human.
Indeed, the delay in skin rejection and GVHD in the NSG
immune humanized models of the present manuscript
are the first ones showing a potent suppressive effect on
human immune responses in vivo. As monocytes in NSG
mice are only detected in the first few days post-hPBMC
injection and rapamycin is needed in this context and
in the allotransplantation model in rat,6 we believe, in
accordance with previous results,9 that IL-34 first acts on
monocytes to differentiate them in M2-like macrophages
which will allow to expand Tregs, creating a regulatory
environment.
Along this line of inhibition of allogeneic immune
responses by IL-34 and prolongation of the rejection-free
post-transplantation period in vivo upon overexpression,
the detection of IL-34 in the sera of patients before kidney transplantation also defined patients who have a
higher probability of having a longer rejection-free posttransplantation period. Thus, and unlike CSF-1, detectable
IL-34 levels in the serum before transplantation could
serve as a biomarker of better kidney transplant outcome.
Still, this finding needs to be confirmed in a larger cohort
and confronted to other cohorts of transplanted patients,
and a correlation with other biological and clinical marker
would be interesting. However, after transplantation, there
was no correlation between rejection and stable patients,
but this could be due to the impact of immunosuppressive
drugs taken by the patients.
Overall, we show that IL-34 is crucial to CD4+ Tregs suppressive function as well as its deficiency led to increased
susceptibility in some autoimmune processes. In human,
the administration of IL-34 represents a new therapeutic
strategy for the treatment of autoimmune diseases, GVHD
and transplant rejection.

4
4.1

METHODS
Animals

Sprague-Dawley (CD) rats were purchased from Charles
River Laboratories, France (L’Arbresle, France) and
C57Bl/6 mice from Janvier Labs (Le Genest-Saint-Isle,
France). The 8–12-week-old NOD/SCID/Il2rg−/− (NSG)
mice were bred in our own animal facilities in SPF
conditions. Il34LacZ/LacZ mice were kindly provided by

Marco Colonna (Washington University, St. Louis, MO).12
Il2rg−/− rats were kindly provided by TRIP Platform
(Nantes, France) and have been previously described.37
The animals were housed in a controlled environment
(temperature 21 ± 1◦ C, 12-h light/dark cycle).

4.2
Generation and genotyping of
Il34−/− SPD rats
rIl34-sgRNA4
(TGTACTGCAGCTTGCCCCGA)
was
designed and generated as previously described.38 Prepubescent females (4–5-week old) were injected with
25-IU pregnant mare serum gonadotropin (Intervet)
and followed 48 h later with 30-IU human chorionic
gonadotropin (Centravet, Plancoet, France) before
breeding.38 Fertilized one-cell stage embryos were collected for subsequent microinjection using a previously
published procedure.38,39
The sgRNA to target rat Il34 (TGTACTGCAGCTTGCCCCGA) was in silico defined using the CRISPOR
software.40 The sgRNA chosen had a cutting frequency
determination (CFD) score of 1, whereas all the other
potential off-target had a weak CFD score I < .4
with at least 3–4 mismatches and these potential offtarget sequences were situated in intergenic or intronic
sequences in chromosomes others than Il34. sgRNA
(10 ng/μl) and Cas9 mRNA (50 ng/μl)38 were comicroinjected into the cytoplasm and nucleus of onecell-stage fertilized embryos. Surviving embryos were
implanted in the oviduct of pseudo-pregnant females
(.5 dpc) and allowed to develop until birth. For genotyping of animals’ ear biopsy specimens from 8- to 10-d-old
rat pups were digested in 250 μl of tissue digestion
buffer (Tris-HCl .1 mol/L [pH 8.3], EDTA 5 mmol/L,
SDS .2%, NaCl .2 mol/L, proteinase K 100 μg/ml) at
56◦ C overnight. PCR amplification was performed on
diluted lysis product (1:20 dilution) and 25 μl of PCR
reaction mix according to the manufacturer instruction (Herculase II Fusion DNA Polymerase, Agilent
Technologies, Les Ulis, France) using the following
PCR primers: forward 5′-AGGTGGAGTACAGACACAGT3′ and reverse 5′-AGATAAGAGGTGGGAGTGAGC-3′. The
following amplification program was used: 1 cycle at 95◦ C
for 5 min, 1 cycle at 62◦ C for 2 min, 35 cycles at 72◦ C
for 30 s, 95◦ C for 10 s, and 60◦ C for 10 s, followed by
1 cycle at 72◦ C for 3 min using a Veriti Thermal Cycler
(Applied Biosystems, Foster City, CA, USA). The PCR
products were analysed by heteroduplex mobility assay
using microfluidic capillary electrophoresis system caliper
LabChip GX (PerkinElmer, Villebon-sur-Yvette, France).
The homozygous Il34−/− specimens were identified from
Il34+/+ littermate as previously described.13

20011326, 2022, 8, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/ctm2.988, Wiley Online Library on [01/11/2022]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

12 of 17

4.3

Bone density

Femurs of Il34+/+ and Il34−/− rats were fixed 24 h in PFA
4%, then trabercular bone mineral density and cortical
tissue mineral density were analysed using the highresolution SkyScan-1076 X-ray microCT system (SkyScan,
Kartuizersweg, Belgium).

4.4

ELISA

Rat CSF-1 was quantified using a rat M-CSF ELISA
(MyBioSource, San Diego, CA, USA). Human CSF-1 and
IL-34 human serum levels were quantified using ELISA
kits (both R&D systems, Mountain View, CA, USA),
according to manufacturer’s instructions. Anti-dsDNA
antibodies were quantified by coating 100 μg/ml of salmon
sperm DNA (Invitrogen) in a 96-well flat-bottom plate
(Thermo Fisher Scientific) in PBS overnight at 4◦ C. After
five washes in PBS-Tween 20 .05%, saturation with PBSBSA 5%-FCS 2% was performed for 1.5 h at 37◦ C. Sera
from Il34+/+ or Il34−/− rats were serially diluted in PBSBSA 1% (1/2, 1/20, 1/200 and 1/2000) and incubated for
1 h at 37◦ C. After 10 washes with PBS-Tween 20 .05%,
an HRP-conjugated goat anti-rat IgG (heavy and light)
(Jackson ImmunoResearch) was used as secondary Ab
(1 h, 37◦ C). After 10 washes with PBS-Tween 20 .05%,
the reaction was visualized by the addition of chromogenic substrate (TMB, BD Biosciences). A stop solution
(H2 SO4 ) was added, and absorbance at 450 nm was measured with reduction at 630 nm using an ELISA plate
reader. Results are expressed in optical density. IgM, IgG,
IgA and IgE were measured in the serum as previously
described.37

4.5

Luminex

Rat serum concentrations of TGFβ1, TGFβ2, TGFβ3,
Eotaxin, MIP-2, MIP-1α, IL-13, IL-1β, IL-1α, IL-2, IL-4,
IL-5, IL-6, IL-10, IP-10, IL-12p70, IL-17A, G-CSF, GMCSF, TNFα, IFNγ, GROα, MCP-1, MCP-3 and RANTES
were quantified using a multiplex kit (MILLIPLEX MAP;
Merck, Burlington, MA and ProcartaPlex; Thermo Fisher,
Waltham, MA) according to manufacturer’s instructions.
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4.7

Total RNA was isolated from cells using a TRIzol reagent
(Invitrogen) or an RNeasy Mini Kit (QIAGEN, Hilden,
Germany). Total RNA was isolated from organs (spleen,
liver, colon and brain) by crushing with Ultra-Turrax
(IKA, Staufen, Germany) using a TRIzol reagent (Invitrogen, Carlsbad, CA), and RNA was reverse transcribed
with random primers and M-MLV reverse transcriptase
(Life Technologies, Carlsbad, CA) according to manufacturer’s instructions. For rat Il34 qPCR, TaqMan (Thermo
Fisher, Waltham, MA) probes were used (Rn01432380_m1;
Thermo Fisher, Waltham, MA). Rat Gapdh, Il17a, Il1b,
Tnfa, Il6, Il22, Ifng, Tgfb, Il10 and Il12p40 qPCR were performed using the Fast SYBR Green Master Mix (Applied
Biosystems, Thermo Fisher Scientific). Probes sequence
and associated Tm are summarized in Table S2. The reaction was performed on the Applied Biosystems StepOne
system (Life Technologies, Carlsbad, CA). Thermal conditions were as follows: 3 s at 95◦ C, 30 s at 60◦ C and
15 s at –5◦ C of the melting temperature with a final melting curve stage. Calculations were made by the ΔΔCT
method.

4.8

Luciferase immunoprecipitation systems was used for the
detection of auto-antibodies against cytokines as previously described.41,42

Histology and immunofluorescence

Rat brains were fixed for 24 h using PFA 4% and conserved by increasing sucrose concentrations and frozen.
Sections were performed from paraffin-embedded tissues
and frozen brain tissues. For histology analysis, slides
were stained with haematoxylin eosin saffron and analysed by an automated tissue slide scanner (Hamamatsu
NanoZoomer Digital Pathology system, Japan) and by
confocal microscopy (Nikon A1 RSi, Tokyo, Japan). For
brain immunofluorescence, slides were incubated with
a purified anti-CD11b/c (a list of the clones and suppliers of all mAbs used in the study in Table S1) and the
staining was revealed using a goat anti-mouse IgG (H+L)AF488 (Invitrogen, Carlsbad, CA). After staining, slides
were mounted with a Prolong Gold Antifade Reagent with
DAPI (Invitrogen, Carlsbad, CA) before analysis with confocal microscopy. The percentage of positive staining was
analysed using ImageJ software.

4.9
4.6
Luciferase immunoprecipitation
systems (LIPS)

qPCR

Cell isolation

Rat spleen was digested by collagenase D (Roche) for
30 min at 37◦ C; the reaction was stopped by adding
.01-mM EDTA. Mice spleen and rats thymic cells and
lymph nodes were isolated by crushing with PBS. Red
blood cells were lysed using a lysis solution (8.29-g NH4Cl,
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1-g KHCO3 , 37.2-mg EDTA/1-L deionized water [pH
7.2–7.4]). Rat TCRαβ− SIRPα+ , TCRαβ+ CD4+ CD25– ,
TCRαβ+ CD4+ CD45RChigh , TCRαβ+ CD4− CD45RChigh ,
TCRαβ+ CD4+ CD25+ CD127low and TCRαβ+ CD4− CD45
RClow/− cells were sorted using an FACS ARIA II (BD
Biosciences, Mountain View, CA). Monoclonal antibodies
are listed in Table S1.

4.10

Phenotypic analysis

Cellular phenotype was analysed on spleen, thymus
and blood using the antibodies listed in Table S1. Cells
were first gated on their morphology, exclusion of
singlets and dead cells by staining with fixable viability dye, eF450 or eF506 (Thermo Fisher, Waltham,
MA), then cells were gated on the expression of
CD45. Rat subsets were identified as follows: DN
(CD4− CD8− ), DN1 (CD4− CD8− CD25− CD44+ ), DN2
(CD4− CD8− CD25+ CD44+ ), DN3 (CD4− CD8− CD25+
CD44− ), DN4 (CD4− CD8− CD25− CD44− ), SP CD4+
(CD4+ CD8− ), SP CD8+ (CD4− CD8+ ), IgM and IgD
expression were analysed among CD45R+ CD45RA+
cells, pDC (TCRαβ− CD4+ CD45R+ ), cDC (TCRαβ−
CD4+/− CD103+ ),
NK
(SIRPa− TCRαβ− CD161++ ),
−
+
+
NKT (SIRPa TCRαβ CD161 ), granulocyte (TCRαβ−
HIS48+ RP-1+ ), macrophage/monocyte (CD68+ ), M1
(CD68+ CD163− ) and M2 (CD68+ CD163+ ). For stimulation, splenocytes were incubated with PMA (50 ng/ml) and
ionomycin (1 μg/ml) for 4 h in the presence of Brefeldin
A (10 μg/ml). Cells were permeabilized with a Fix/Perm
kit (Thermo Fisher, Waltham, MA). Abs were used to
stain cells, and fluorescence was measured with a BD
FACSCanto II flow cytometer (BD Biosciences, Mountain
View, CA), and FlowJo software was used to analyse
data.

4.11

Proliferation assay

Sorted rat TCRαβ+ CD4+ CD25– and TCRαβ+ CD4−
CD45RChigh Teffs, TCRαβ+ CD4+ CD25+ CD127low and
TCRαβ+ CD4− CD45RClow/− Treg cells from Il34+/+ and
Il34−/− rats were plated in duplicate or triplicate with
stimulating coated αCD3 (G4.18 at 1, .5 and .25 μg/ml) and
soluble αCD28 (JJ319 at 10 μg/ml) mAbs in 100 or 200-μl
complete RPMI-1640 medium in round- or V-bottomed
96-well plates, at 37◦ C and 5% CO2 . Proliferation of CFSElabelled TCRαβ+ CD4+ CD25– , TCRαβ+ CD4− CD45RChigh ,
TCRαβ+ CD4− CD45
TCRαβ+ CD4+ CD25+ CD127low ,
low/−
T cells were analysed by flow cytometry 2 or 3
RC
days later by gating on TCRαβ+ CD4+ cells among living
cells (DAPI− ).

4.12

Acute DSS colitis in rats

DSS (TdB labs, Sweden) was dissolved in drinking water at
5.5% and given to 9-week-old male rats for 7 days. Weight
loss and a disease activity index (DAI = clinical score) were
assessed every day. Score is defined as follows: stool consistency – 0 (normal), 2 (loose stool) and 4 (diarrhoea);
and bleeding – 0 (no blood), 2 (visual pellet bleeding) and
4 (gross bleeding, blood around anus). At day 7, animals
were sacrificed, and colon length was measured and H&E
stained to estimate the inflammation.

4.13

TNBS-induced colitis in mice

The model of colitis was induced by the rectal administration of TNBS (100 mg/kg in .1 ml; Merck, Burlington,
MA) in 50% ethanol. Animals were weighed daily and were
sacrificed 3 days post-injection to measure colon length.

4.14
Experimental autoimmune
encephalomyelitis (EAE)
Eight-week-old Il34+/+ or Il34LacZ/LacZ C57BL/6J female
mice12 were immunized by a subcutaneous injection of
100 μl of an emulsion containing 200 μg of MOGp35–55
(GeneCust, Boynes, France) in complete Freunds adjuvant (Merck, Burlington, MA) supplemented with 400-μg
heat-killed Mycobacterium tuberculosis (Thermo Fischer,
Waltham, MA). An amount of 200-ng Bordetella pertussis toxin (Merck, Burlington, MA) in 100 μl of PBS was
injected intraperitoneally on the same day and 2 days after
immunization. Adenovirus, coding for murine IL-34 or
null, were injected i.v. at 4.109 IP/100 μL/mice 2 days before
the immunization. Rapamycin was i.p. injected every day
for 15 days at .25 mg/kg (Rapamune, Pfizer). Animals were
monitored daily from day 5 and scored on a 5-point scale
as follows: 0, no symptoms; .5, tip of tail is limp; 1, loss of
total tail tonus; 1.5, loss of total tail tonus and hind leg inhibition; 2, loss of total tail tonus and weakness of hind legs;
2.5, loss of total tail tonus and dragging of hind legs; 3, loss
of total tail tonus complete and paralysis of hind legs; 3.5,
loss of total tail tonus and paralyzed hind legs are together
on one side of the body; 4, loss of total tail tonus, hind leg
and partial front leg paralysis; 4.5, loss of total tail tonus,
hind leg and front leg paralysis, 5: mouse is found dead
due to paralysis. Due to ethical considerations mice were
sacrificed when they reached grade 4 for 24 h.

4.15

Wasting disease

Il2rg−/− SPD rats aged of 6 weeks were injected via the tail
vein with 2.5 × 106 sorted TCRαβ+ CD4+ CD45RChigh
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Teff cells from Il34+/+ rats in association or not
or
with
sorted
TCRαβ+ CD4+ CD25+ CD127low
+
−
TCRαβ CD4 CD45RClow/− Tregs from Il34+/+ or Il34−/−
rats at a Teffs:Tregs ratio of 3.5:1 and 2.1:1, respectively. A
control with a PBS injection was also performed.

For the DIVAT cohort, all recruited patients gave signed
informed consent.

4.16
3′ Differential gene expression
(DGE) RNA-sequencing

Serum samples from kidney +/− pancreas transplanted
patients were obtained thanks to the ‘Données Informatisées et VAlidées en Transplantation’ DIVAT Biocollection
(www.divat.fr, French Research Ministry: RC12_0452, last
agreement No 13 334, No CNIL for the cohort: 891735)
collected between 2004 and 2012, aliquoted and stored
at −80◦ C. All recruited patients gave signed informed
consent. Table S3 recapitulates the clinical characteristics.

Total mRNA from sorted TCRαβ+ CD4+ CD25– and
TCRαβ+ CD4− CD45RChigh Teffs, TCRαβ+ CD4+ CD25+
CD127low Tregs, TCRαβ+ CD4− CD45RClow/− T cells from
Il34+/+ and Il34−/− rats were extracted using an RNeasy
Mini Kit (QIAGEN, Hilden, Germany) and protocol of
3′ DGE RNA sequencing was performed as previously
described.16 The differential expression p values were
processed with DESeq2.43 The data are available at
PRJEB52489.

4.17

Immune humanized mouse models

For xenogeneic graft-versus-host-disease (GVHD) model,
1.5 × 107 fresh human PBMC were intravenously injected
in 1.5-Gy-irradiated NSG mice as previously described.10
Human PBMC engraftment was monitored in blood, and
GVHD development was characterized by ≥20% body
weight loss. For the skin rejection model, human skins
were obtained from healthy donors from abdominoplasty
surgery, and transplantation was performed as previously
described.10 A total of 5.0 × 106 PBMCs, allogeneic to the
graft, were i.v. injected. A graft rejection score was established from 0 to 5 based on macroscopic observations: 1,
the skin starts to peel off; 2, thick skin; 3, scab; 4, edges
start to take off; 5, the skin is entirely gone. Osmotic pumps
(Alzet, model 1004, Cupertino, CA) were filled with rhIL34 (.42 μg/h, i.e. .4 m/kg/d; Thermo Fisher, Waltham, MA
or Preprotech, Neuilly-Sur-Seine, France) and placed i.p.
on the day before the injection of the PBMC. Rapamycin
(.4 mg/kg/d for 10 days, Rapamune, Pfizer) was injected
intraperitoneally.

4.18

4.19
DIVAT cohort of kidney
transplanted patients

4.20

Statistics

Mann–Whitney U test was used for qPCR, FACS, positive area in immunohistofluorescence and ELISA analysis.
Mantel Cox Log Rank test was used to analyse survival
curves. Two-way ANOVA and a Bonferroni post-test were
used to compare weight loss and clinical score between
groups. Adapted controls were performed together with
the test conditions. Animal numbers were determined
with ethical committee agreement.
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